Understand the source comparison
LL-37 Mold Illness Results Timeline Expect: Treatment Protocol Comparison
Before implementing any LL-37 protocol, understanding how different approaches compare in timeline, mechanism, and outcome helps set realistic expectations. LL-37 Monotherapy (Subcutaneous) 100–200 µg daily or every other day 4–8 weeks for initial improvement;
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Before implementing any LL-37 protocol, understanding how different approaches compare in timeline, mechanism, and outcome helps set realistic expectations.
- LL-37 Monotherapy (Subcutaneous)
- 100–200 µg daily or every other day
- 4–8 weeks for initial improvement; 12–16 weeks for stabilisation
- Direct antimicrobial activity, immune modulation, mucosal repair
- Vitamin D optimisation (>50 ng/mL), zinc sufficiency, glutathione support
- Most effective when mold exposure is eliminated and cofactors are addressed. Limited efficacy as standalone intervention without environmental remediation
- LL-37 + Binder Protocol
- LL-37 as above + cholestyramine or activated charcoal daily
- 3–6 weeks for initial improvement; 10–14 weeks for stabilisation
- Peptide restores immunity while binders accelerate mycotoxin clearance
- Same as monotherapy + hydration (binders cause constipation without adequate water intake)
- Accelerates Phase 2 (pathogen clearance) by reducing mycotoxin reabsorption in the gut. Particularly effective for patients with high urinary mycotoxin levels
- LL-37 + Thymic Peptide Stack
- LL-37 daily + Thymalin 5–10 mg 2–3×/week
- 2–5 weeks for initial improvement; 8–12 weeks for stabilisation
- LL-37 handles innate immunity; thymic peptides restore adaptive immune regulation (T-cell function, cytokine balance)
- Vitamin D, zinc, selenium (required for thymic function)
- Addresses both arms of immune dysfunction. Fastest timeline for patients with severe CIRS and autoimmune cross-reactivity
- Vitamin D Monotherapy (No LL-37)
- 5,000–10,000 IU daily to achieve 50–80 ng/mL
- 8–16 weeks for modest improvement; incomplete symptom resolution common
- Upregulates endogenous LL-37 production via VDR pathway
- Magnesium, vitamin K2 (required for safe high-dose D3)
- Slower than exogenous LL-37 but sufficient for mild cases. Ineffective when VDR gene expression is severely suppressed by mycotoxins